Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hair Regrowth Following Partial Thickness Removal of SSCIS

2. september 2026 opdateret af: Naomi Lawrence, The Cooper Health System

Hair Regrowth Following Partial Thickness Stages in Mohs Micrographic Surgery of Squamous Cell Carcinoma in Situ: A Prospective Pilot Study

Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp. Standard surgical techniques may remove deeper structures that contain hair follicles, which can result in permanent hair loss. This study evaluates whether a modified surgical technique, known as partial thickness excision, can preserve hair growth and improve cosmetic outcomes. Participation involves minimal risk beyond the standard risks of Mohs surgery. If patients choose to participate, their surgery will be performed using this technique, and photographs will be taken over time to evaluate hair regrowth and healing.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

15

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Adults ≥ 18 years old
  • Histologically confirmed SCCIS
  • Lesions located in the hair-bearing scalp
  • Ability to provide informed consent

Exclusion Criteria:

  • Invasive, poorly differentiated, or high-risk SCC features (e.g., perineural invasion)
  • Recurrent SCC at the same site
  • Prior radiation therapy to the scalp
  • Scarring alopecia or active inflammatory scalp disease at the treatment site
  • Immunosuppression that, in the investigator's judgement, increases oncologic risk
  • Use of topical minoxidil, oral minoxidil, finasteride, spironolactone, or other hair-growth promoting agents

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Partial Thickness Excision
Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential.
Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hair Growth measured clinically by hair density percentage compared to baseline photo
Tidsramme: 3 and 6 months post-procedure.
To evaluate hair growth following partial thickness excision of SCCIS at 3 and 6 months post-procedure.
3 and 6 months post-procedure.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clearance of SCCIS measured by Mohs surgeons' interpretation of margins on surgical slides.
Tidsramme: Immediately following the final Mohs stage during the index procedure
To assess clinical and histologic clearance of SCCIS treated with partial-thickness excision.
Immediately following the final Mohs stage during the index procedure
Patient Satisfaction measured via patient satisfaction questionnaire
Tidsramme: 3 and 6 months post-procedure

To evaluate patient-reported satisfaction with hair density and cosmetic outcome.

"Are you satisfied with amount of hair//appearance of skin/result of treatment?" etc. on scale of 1-10. 1 being not satisfied and 10 being very satisfied/.

3 and 6 months post-procedure
Complications
Tidsramme: 2 weeks post-procedure, 3 months post-procedure, and 6 months post-procedure
To document wound-healing, complications, and the need for additional treatment.
2 weeks post-procedure, 3 months post-procedure, and 6 months post-procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

17. juli 2027

Studieafslutning (Anslået)

17. juli 2028

Datoer for studieregistrering

Først indsendt

4. august 2026

Først indsendt, der opfyldte QC-kriterier

2. september 2026

Først opslået (Faktiske)

9. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. september 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner